Clinical Trial Update: A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the safety and efficacy of SYH2053 in Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mixed Hyperlipidemia
• Non-familial Hypercholesterolemia

Drugs mentioned

• SYH2053

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Status: NOT_YET_RECRUITING